SBIO250117C40000
- 3.99
- 0.000.00%
Alps Etf Trust Medical Breakthroughs Etf Newsroom
Axsome Reveals Data From Alzheimer's Studies, Analyst Sees Hope Despite Mixed Trial Results
HC Wainwright & Co. Reiterates Buy on Axsome Therapeuticsto Buy
Expert Outlook: Axsome Therapeutics Through The Eyes Of 8 Analysts
Needham Reiterates Buy on Axsome Therapeutics, Maintains $130 Price Target
Axsome Therapeutics Analyst Ratings
Axsome Therapeutics, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Axsome Completes Phase 3 Trials for AXS-05 in Alzheimer's Agitation, Plans FDA Submission for Alzheimer's Agitation Drug in 2025
Mizuho CEO Sees Global Boom in M&A After Trump Takes Office
Rhythm Gets FDA Approval for Imcivree for Toddlers
Catalyst Watch: Labor Pains for Amazon & Starbucks, Nasdaq Call-up for MicroStrategy and Pony AI Ratings
Rhythm Pharmaceuticals' Obesity Treatments Target Less Crowded Space, Analyst Sees Long-Term Potential
Hythm Pharmaceuticals Secures FDA Approval For Expanded Use Of IMCIVREE To Treat Obesity In Children As Young As 2 With Bardet-Biedl Syndrome Or MC4R Pathway Deficiencies, Targeting Rare Neuroendocrine Diseases
Five Reasons Why UBS Is Overweight the UK
J.P. Morgan's Top Healthcare Stocks for 2025
This S&P Global Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Forecasting The Future: 14 Analyst Projections For Rhythm Pharmaceuticals
Avidity Biosciences Analyst Ratings
PepGen Stock Craters 35% on FDA Clinical Hold
Crinetics Pharmaceuticals Analyst Ratings
Neurocrine's Drug Gains FDA Nod As First Targeted Treatment For Certain Type Of Inherited Disorder, Analyst Highlights Blockbuster Potential